This article about the vaccine court and SIRVA claims was written by Dorit Rubinstein Reiss, Professor of Law at the University of California Hastings College of the Law (San Francisco, CA), who is a frequent contributor to this and many other blogs, providing in-depth, and intellectually stimulating, articles about vaccines, medical issues, social policy, and the law.
Professor Reiss writes extensively in law journals about the social and legal policies of vaccination. Additionally, Reiss is also a member of the Parent Advisory Board of Voices for Vaccines, a parent-led organization that supports and advocates for on-time vaccination and the reduction of vaccine-preventable disease. She is also a member of the Vaccines Working Group on Ethics and Policy.
In this article, we are going to take a look at how “shoulder injury related to vaccine administration” (SIRVA) relates to the National Vaccine Injury Compensation Program (NVICP), often called the Vaccine Court, claims. In 1986, the United States Congress passed the National Childhood Vaccine Injury Act, which among other things created the NVICP. The act’s main goal was to protect vaccine manufacturers from vaccine injury claims and liability–but not for the reasons you might think.
Congress was rightly concerned that the costs for these legal actions were going to drive most, if not all, manufacturers from the USA market. That would have been a horrific problem for the country, with no ability to protect children from deadly and dangerous diseases.
The NVICP provides a no-fault program to resolve vaccine injury claims – “quickly, easily, with certainty and generosity.” The program was (and continues to be) funded by a tax on all vaccines sold in the country. Moreover, using a system of expert administrative “judges” (called Special Masters), a petitioner seeking to establish causation-in-fact must show, by a preponderance of the evidence, that but for the vaccination, they would not have been injured, and that the vaccination was a substantial factor in bringing about their injury.
The NVICP works reasonably well to compensate any real victims of vaccine injury, though, like any system, it is not perfect. For example, a panel of three special masters began hearing the first cases of the historic Omnibus Autism Proceedings (along with the Mini-Omnibus decision) in June 2007. They decided that there was absolutely no evidence, confirmed by peer-reviewed clinical research, that there was a link between vaccines and autism spectrum disorders.
Despite some frequent claims that the “huge payouts” from NVICP are indicative of the dangers of vaccines, the data support the extremely high safety profile of vaccines and shows they are incredibly important in preventing pathogenic diseases.
Here is the compensation data, from 01 January 2006 through 31 December 2017, as published by the HRSA:
- Over 3.45 billion doses of covered vaccines were distributed in the USA. Of that, 4,408 claims that were compensated by the NVICP, which were filed in this time period – that’s 0.000128% of all vaccines delivered;
- put another way, that means that for every 1 million doses of vaccine that were distributed, approximately 1 individual was compensated. In the world of medicine, a procedure that has that tiny injury rate should be considered nearly perfect;
- furthermore, most of these claims (3214) were settled – and settlements do not require showing causation, and do not mean the claim has merit. As the HRSA explains:
What reasons might a claim result in a negotiated settlement? – Prior to a decision by the U.S. Court of Federal Claims, both parties decide to minimize the risk of loss through settlement.
–A desire to minimize the time and expense of litigating a case
–The need to resolve a case quickly
- Since 1988, approximately US$4.2 billion have been paid to 6,713 claims that were determined to be related to vaccines. Yes, it seems like a large number, but again, based on the billions of doses of vaccines delivered, the number of cases is extremely small – it’s about $1.22 per dose of vaccine.
- There are a number of myths about the NVICP compensation, but the misuse of this data is among the most egregious.
These numbers for vaccine injury claims are so small that we ought to take pride in the medical miracle of vaccines. Moreover, the NVICP is a fairly efficient system in taking care of those who may be injured by vaccines. Furthermore, researchers watch over the claims, since they really work to show causality, to determine how to make next-generation vaccines better and safer.
There are two ways a petitioner can show causation in NVICP. One way is to prove that your case is covered by the “table” that establishes what injuries have some relationship to a vaccine. The other is to prove an off-table injury by showing that more likely than not the vaccine caused the injury.
Even there, however, petitioners get a break. Petitioners don’t need to show that science supports a causal connection between the vaccine and the problem. If they provide an expert that suggests a plausible theory, that can be enough – though the other side may counter it with their own experts.
It’s a good system, maybe even a great one. It makes it relatively easy for the injured to get generous compensation, without forcing them to go through a difficult set of procedures to win a tort case. And it doesn’t allow for spurious claims based on bad science, anecdotes, and nonsense. That’s also good.
SIRVA in the Vaccine Court
Recently, a new set of vaccine injury claims have made the rounds in real news services. Several large payouts have been made to individuals after receiving a flu vaccine, including US$1 million to a nurse in Louisiana. Already, some anti-vaccination websites are trying to say “gotcha!” But, as I’ve said time and again it’s the nuanced information that is a “gotcha.”
Although the injuries were caused by flu vaccination, they were not caused by the vaccine itself.
Here’s what happens. A flu vaccine must be delivered intramuscularly, that is, directly into the muscle. Generally, a healthcare worker will pinch the muscle on the upper arm (the deltoid muscle) in an attempt to deliver the vaccine into the muscle. The upper arm tends to have less subcutaneous fat, so it is considered the best location for flu vaccines.
Most package inserts for flu vaccines recommend 1-inch needles (although medicine is nearly 100% metric, for some obscure reason, needle length remains in inches for most of the world) for adults and ½-inch needles for children so that the injection actually gets into the deltoid muscle.
Unfortunately, there are a lot of nerves, blood vessels, ligaments, and other important physiological structures in this area. And if the injection is done improperly there can be painful and sometimes permanent damage to this area of the deltoid muscle. This muscle is incredibly important for the large range of motion of the arms around the shoulder. When it is in pain, usually even if it is in just one small part of the range of motion, it can be debilitating.
Up until a few years ago, the NVICP only compensated for vaccine injury claims that involved the actual contents of the vaccine. Now they will compensate patients that have been diagnosed with shoulder injury related to vaccine administration (SIRVA).
Now just to be clear, SIRVA could happen with any intramuscular injection (vaccine or otherwise) that uses a long needle into the deltoid muscle. Diabetics, for example, use shorter needles and are taught to inject insulin into fatty areas of the arm, thigh, and abdomen. But if a diabetic used the wrong size needle and went too high on the arm, they could cause a SIRVA-like issue.
SIRVA generally is caused by a vaccine injected improperly high on the arm. This can damage musculoskeletal structures of the shoulder, such as tendons, ligaments, or bursa, causing sudden shoulder pain. There is simply no relationship to the contents of flu, or any other, vaccine.
Other recommendations to prevent SIRVA were suggested in a recent article, “How to give — and receive — a safe shot”:
- An intramuscular vaccination in the arm should avoid the top third of the deltoid muscle and aim for the middle of the muscle, its thickest portion.
- Both the patient and the provider should be on the same plane — that is, either both sitting or both standing, although sitting is preferred. This reduces the risk of inadvertently injecting the vaccine too high up into the shoulder. (When I received the injection that led to problems, I was sitting down and the nurse was standing up). It is also a good idea to hold the arm out a little from the side, a position that helps protect the bursa.
- The injection should go into the muscle at a 90-degree angle to the skin.
- The Centers for Disease Control and Prevention provides specific recommendations for needle size based on the patient’s weight, but generally “the needles get bigger as the patient gets bigger,’’ says JoEllen Wolicki, a nurse educator in CDC’s immunization services division.
For patients and practitioners, the CDC’s website has illustrations and recommendations describing proper vaccine protocols.
Proposed rules for SIRVA in the vaccine court
As already mentioned, the vaccine court has already been compensated for claims of SIRVA. What has changed – and the reason for the article – is that the Department of Health and Human Services (DHHS) included a proposal to add SIRVA to the Table of Injuries as part of a new rule.
Two issues need clarifying: what does adding SIRVA to the Vaccine Court Table mean, and what is a proposed rule.
The new rule adds SIRVA developing within 48 hours of injection as an injury to all vaccines injected into the muscle. It also has added the injury to MMR, varicella, and MMRV even though those vaccines are not currently injected into the muscle to avoid having to change the table if vaccines that need to be injected into the muscle are developed. A petitioner would not be compensated for injuries from these vaccines with the current version that is not injected into the muscle.
DHHS has published a rule including various changes to the Table of Injuries on the site – there is now a comment period when anyone can submit comments. These can be submitted until January 25, 2016 – a lengthy and generous period. Then the agency will consider the comments and issue a final rule, with an explanation of its decisions.
This is a chance for those with opinions on the table to provide input and affect its contents. Until the rule is finalized, SIRVA is not part of the Table – though petitioners can still win cases as off-table injuries.
What adding the injury to the table means is that for people who develop SIRVA within 48 hours of vaccinating, there will be a presumption that the vaccination caused the harm. That should make getting compensation for these vaccine injury claims easier and quicker.
This article about SIRVA was originally published in August 2015. It has been updated with new data, repair of broken links, and new information about SIRVA being added to the table of vaccine injuries.
Please comment below, positive or negative. Of course, if you find spelling errors, tell me! And share this article.
There are two ways you can help me out to keep this website awesome. First, you can make a monthly contribution through Patreon:Become a Patron!
Buy ANYTHING from Amazon.